AGTC Announces Completion of Enrollment in All Adult Dose Groups of Its Ongoing Phase 1/2 Clinical Trials in Patients With Achromatopsia
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has completed the planned enrollment in all dose groups for adult patients (age 18 years or older), including […]
AGTC Announces Completion of Enrollment in the Two Highest Dose Groups of Its Ongoing Phase 1/2 Clinical Trial in Patients With X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has completed enrollment in the two highest dose groups of its Phase 1/2 clinical trial evaluating the safety […]
AGTC Announces Agenda for R&D Day on January 28, 2020 in New York
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it will host an R&D Day beginning at 7:30 am ET on Tuesday, January 28, 2020, in New York. […]
AGTC Reports Positive Six-Month Data From Its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, reported positive interim six-month data from its ongoing Phase 1/2 clinical program in X-linked retinitis pigmentosa (XLRP). The results show that […]
AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has identified Stargardt disease as the second ophthalmology program in its previously announced preclinical pipeline expansion, which also […]
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
UF startup Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced that they have entered into a strategic collaboration to co-develop and co-commercialize an […]
AGTC to Present at Upcoming Conferences
UF startup Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that management will be participating in the following conferences: 14th Annual Wells Fargo Securities Healthcare Conference – Boston (September 4-5, 2019) 21st Annual H.C. Wainwright Global Investment Conference […]
AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study
UF startup and UF Innovate│Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has completed enrollment of the third group in the dose-escalation portion of its Phase 1/2 clinical trial evaluating the safety […]
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019
UF startup Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced financial results for the quarter ended March 31, 2019. AGTC is a graduate of UF Innovate | Sid Martin Biotech. “Completing enrollment in the dose escalation portion of our […]
AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials
UF startup Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has achieved enrollment milestones in two of its Phase 1/2 clinical trials. The company completed enrollment of the dose escalation portion of the achromatopsia (ACHM) CNGB3 trial, […]